The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gvozdeva A.D.

Chazov National Medical Research Center for Cardiology

Sobolevskaya M.S.

Chazov National Medical Research Center for Cardiology

Sharf T.V.

Chazov National Medical Research Center for Cardiology

Kuznetsova T.V.

Chazov National Medical Research Center for Cardiology

Masenko V.P.

Chazov National Medical Research Center for Cardiology

Ageev F.T.

Chazov National Medical Research Center for Cardiology

Ovchinnikov A.G.

Chazov National Medical Research Center for Cardiology

Influence of sacubitril/valsartan on exercise tolerance, left ventricular mass index and diastolic function in patients with HFpEF and left ventricular hypertrophy

Authors:

Gvozdeva A.D., Sobolevskaya M.S., Sharf T.V., Kuznetsova T.V., Masenko V.P., Ageev F.T., Ovchinnikov A.G.

More about the authors

Journal: Russian Cardiology Bulletin. 2023;18(3): 67‑75

DOI: 10.17116/Cardiobulletin20231803167

Read: 1628 times

Contact the author
Table of contents

INFLUENCE OF SACUBITRIL/VALSARTAN ON EXERCISE TOLERANCE, LEFT VENTRICULAR MASS INDEX AND DIASTOLIC FUNCTION IN PATIENTS WITH HFPEF AND LEFT VENTRICULAR HYPERTROPHY
INFLUENCE OF SACUBITRIL/VALSARTAN ON EXERCISE TOLERANCE, LEFT VENTRICULAR MASS INDEX AND DIASTOLIC FUNCTION IN PATIENTS WITH HFPEF AND LEFT VENTRICULAR HYPERTROPHY

To cite this article:

Gvozdeva AD, Sobolevskaya MS, Sharf TV, Kuznetsova TV, Masenko VP, Ageev FT, Ovchinnikov AG. Influence of sacubitril/valsartan on exercise tolerance, left ventricular mass index and diastolic function in patients with HFpEF and left ventricular hypertrophy. Russian Cardiology Bulletin. 2023;18(3):67‑75. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20231803167

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

OBJECTIVE

To assess the effect of neprilysin/angiotensin receptor inhibitor (sacubitril/valsartan, S/V) on exercise capacity, left ventricular (LV) mass index and diastolic function, serum NT-proBNP in patients with chronic HFpEF and concentric LV hypertrophy.

MATERIAL AND METHODS

A prospective single-center trial enrolled 45 patients with chronic HFpEF NYHA class II―III, moderate/severe hypertensive concentric LV hypertrophy (LV mass index ≥132 g/m2 for men or ≥109 g/m2 for women) and increased LV filling pressures at rest and/or during exercise. All participants were randomly assigned in an open-label fashion to receive S/V 50–200 mg daily or to the control group (individualized therapy including ACE inhibitors or ARBs) with a ratio of 2:1 for 6 months. At baseline and after 6 months, all participants underwent echocardiography at rest and during exercise, a 6-minute walk test and laboratory testing.

RESULTS

In the S/V group, 6MWD increased by 20 m (95% CI 12—28), quality of life improved (Minnesota Questionnaire) by 5 points (95% CI –8— –2), left ventricular mass index decreased by 17 g/m2 (95% CI –21— –13), indexed left atrial volume decreased by 2.8 ml/m2 (95% CI –9.2— –0.8), E/e′ ratio decreased by 1.8 (95% CI –3.2— –0.02) and serum NT-proBNP decreased by 26% (95% CI –53— –2%; p<0.05) after 6 months compared to the control group.

CONCLUSION

Treatment with S/V was associated with improvement in exercise capacity and reduction of LV hypertrophy and LV filling pressure, improved diastolic reserve and decrease of serum NT-proBNP in patients with HFpEF and advanced LV hypertrophy.

Keywords:

neprilysin inhibitor
natriuretic peptide
heart failure with preserved ejection fraction

Authors:

Gvozdeva A.D.

Chazov National Medical Research Center for Cardiology

Sobolevskaya M.S.

Chazov National Medical Research Center for Cardiology

Sharf T.V.

Chazov National Medical Research Center for Cardiology

Kuznetsova T.V.

Chazov National Medical Research Center for Cardiology

Masenko V.P.

Chazov National Medical Research Center for Cardiology

Ageev F.T.

Chazov National Medical Research Center for Cardiology

Ovchinnikov A.G.

Chazov National Medical Research Center for Cardiology

Received:

23.05.2023

Accepted:

28.06.2023

Close metadata

References:

  1. Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: New approaches to diagnosis and management. Clinical Cardiology. 2020;43(2):145-55.  https://doi.org/10.1002/clc.23321
  2. Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R, Chirinos JA, Collins S, Deo RC, Gladwin MT, Granzier H, Hummel SL, Kass DA, Redfield MM, Sam F, Wang TJ, Desvigne-Nickens P, Adhikari BB. Research Priorities for Heart Failure with Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary. Circulation. 2020;141(12):1001-1026. https://doi.org/10.1161/CIRCULATIONAHA.119.041886
  3. Ageev FT, Ovchinnikov AG. Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes. Kardiologiia. 2022;62(7):44-53. (In Russ.). https://doi.org/10.18087/cardio.2022.7.n2058
  4. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-Specific Treatment of Heart Failure with Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016;134(1):73-90.  https://doi.org/10.1161/CIRCULATIONAHA.116.021884
  5. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E. How to diagnose heart failure with preserved ejection fraction: the HFA—PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297-3317. https://doi.org/10.1093/eurheartj/ehz641
  6. Ovchinnikov A, Belyavskiy E, Potekhina A, Ageev F. Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort Study. Journal of Clinical Medicine. 2022;11(13):3885. https://doi.org/10.3390/jcm11133885
  7. Nakamura T, Tsujita K. Current trends and future perspectives for heart failure treatment leveraging cGMP modifiers and the practical effector PKG. Journal of Cardiology. 2021;78(4):261-268.  https://doi.org/10.1016/j.jjcc.2021.03.004
  8. Van Heerebeek L, Hamdani N, Falcão-Pires I, Leite-Moreira AF, Begieneman MPV, Bronzwaer JGF, van der Velden J, Stienen GJM, Laarman GJ, Somsen A, Verheugt FWA, Niessen HWM, Paulus WJ. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126(7):830-839.  https://doi.org/10.1161/CIRCULATIONAHA.111.076075
  9. Nordén ES, Bendiksen BA, Andresen H, Bergo KK, Espe EK, Hasic A, Hauge-Iversen IM, Veras I, Hussain RI, Sjaastad I, Christensen G, Cataliotti A. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload. ESC Heart Failure. 2021;8(2):918-927.  https://doi.org/10.1002/ehf2.13177
  10. Cunningham JW, Claggett BL, O’Meara E, Prescott MF, Pfeffer MA, Shah SJ, Redfield MM, Zannad F, Chiang L-M, Rizkala AR, Shi VC, Lefkowitz MP, Rouleau J, McMurray JJV, Solomon SD, Zile MR. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. Journal of the American College of Cardiology. 2020;76(5):503-514.  https://doi.org/10.1016/j.jacc.2020.05.072
  11. Ovchinnikov AG, Gvozdeva AD, Blankova ZN, Borisov AA, Ageev FT. The Role of Neprilysin Inhibitors in the Treatment of Heart Failure with Preserved Ejection Fraction. Kardiologiia. 2020;60(11):117-127. (In Russ.). https://doi.org/10.18087/cardio.2020.11.n1352
  12. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014;371(11):993-1004. https://doi.org/10.1056/NEJMoa1409077
  13. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen H-D, Goncalvesova E, Katova T, Saraiva JFK, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP. Angiotensin—neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine. 2019;381(17):1609-1620. https://doi.org/10.1056/NEJMoa1908655
  14. Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O’Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD; PARAGON-HF Investigators. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. Journal of the American College of Cardiology. 2019;74(23):2858-2873. https://doi.org/10.1016/j.jacc.2019.09.063
  15. Buckley LF, Canada JM, Del Buono MG, Carbone S, Trankle CR, Billingsley H, Kadariya D, Arena R, Van Tassell BW, Abbate A. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Failure. 2018;5(2):372-378.  https://doi.org/10.1002/ehf2.12235
  16. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2015;28(1):1-39.e14.  https://doi.org/10.1016/j.echo.2014.10.003
  17. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2016;29(4):277-314.  https://doi.org/10.1016/j.echo.2016.01.011
  18. Ovchinnikov AG, Ageev FT, Alekhin MN, Belenkov YuN, Vasyuk YuA, Galyavich AS, Gilyarevskiy SR, Lopatin YM, Mareev VYu, Mareev YuV, Mitkov VV, Potekhina AV, Prostakova TS, Rybakova MK, Saidova MA, Khadzegova AB, Chernov MYu, Yuschuk EN, Boytsov SA. The role of diastolic transthoracic stress echocardiography with incremental workload in the evaluation of heart failure with preserved ejection fraction: indications, methodology, interpretation. Expert consensus developed under the auspices of the National Medical Research Center of Cardiology, Society of Experts in Heart Failure (SEHF), and Russian Association of Experts in Ultrasound Diagnosis in Medicine (REUDM). Kardiologiia. 2020;60(12):48-63. (In Russ.). https://doi.org/10.18087/cardio.2020.12.n1219
  19. Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, Shi V, Zhao Z, Cowie MR; PARALLAX Investigators and Committee members. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA. 2021;326(19):1919-1929. https://doi.org/10.1001/jama.2021.18463
  20. McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer N, Vardeny O, Claggett B, Jhund PS, Solomon SD. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation. 2020;141(5):338-351.  https://doi.org/10.1161/CIRCULATIONAHA.119.044491
  21. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387-1395. https://doi.org/10.1016/S0140-6736(12)61227-6
  22. Wachter R, Pieske B, Baldridge A, Ibram G, Zhao Z, Shah SJ, PARALLAX Investigators, Reduction in heart failure hospitalizations by sacubitril/valsartan; a post-hoc analysis of the PARALLAX trial. European Heart Journal. 2022;43(suppl 2):ehac544.791.  https://doi.org/10.1093/eurheartj/ehac544.791
  23. Tashiro K, Kuwano T, Ideishi A, Morita H, Idemoto Y, Goto M, Suematsu Y, Miura SI. Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect. Cardiology Research. 2020;11(6):376-385.  https://doi.org/10.14740/cr1137
  24. Nordén ES, Bendiksen BA, Andresen H, Bergo KK, Espe EK, Hasic A, Hauge-Iversen IM, Veras I, Hussain RI, Sjaastad I, Christensen G, Cataliotti A. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload. ESC Heart Failure. 2021;8(2):918-927.  https://doi.org/10.1002/ehf2.13177
  25. Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O’Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD; PARAGON-HF Investigators. Echocardiographic Features of Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction. Journal of the American College of Cardiology. 2019;74(23):2858-2873. https://doi.org/10.1016/j.jacc.2019.09.063
  26. Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC: Cardiovascular Imaging. 2020;13(1 Pt 2):245-257.  https://doi.org/10.1016/j.jcmg.2018.12.034
  27. Kosmala W, Przewlocka-Kosmala M, Rojek A, Mysiak A, Dabrowski A, Marwick TH. Association of Abnormal Left Ventricular Functional Reserve with Outcome in Heart Failure With Preserved Ejection Fraction. JACC: Cardiovascular Imaging. 2018;11(12):1737-1746. https://doi.org/10.1016/j.jcmg.2017.07.028
  28. Takagi T, Takagi A, Yoshikawa J. Elevated left ventricular filling pressure estimated by E/E′ ratio after exercise predicts development of new-onset atrial fibrillation independently of left atrial enlargement among elderly patients without obvious myocardial ischemia. Journal of Cardiology. 2014;63:128.  https://doi.org/10.1016/j.jjcc.2013.06.019
  29. Croteau D, Qin F, Chambers JM, Kallick E, Luptak I, Panagia M, Pimentel DR, Siwik DA, Colucci WS. Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice with Obesity-Related Metabolic Heart Disease. JACC: Basic to Translational Science. 2020;5(9):916-927.  https://doi.org/10.1016/j.jacbts.2020.07.006
  30. Nordén ES, Bendiksen BA, Andresen H, Bergo KK, Espe EK, Hasic A, Hauge-Iversen IM, Veras I, Hussain RI, Sjaastad I, Christensen G, Cataliotti A. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload. ESC Heart Failure. 2021;8(2):918-927.  https://doi.org/10.1002/ehf2.13177
  31. Cassano V, Armentaro G, Magurno M, Aiello V, Borrello F, Miceli S, Maio R, Perticone M, Marra AM, Cittadini A, Hribal ML, Andreozzi F, Sesti G, Sciacqua A. Short-term effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure. Frontiers in Pharmacology. 2022;13:1069828. https://doi.org/10.3389/fphar.2022.1069828
  32. Du H, Li X, Zhao W, Jiang N. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure. Journal of Healthcare Engineering. 2022;2022:9494981. https://doi.org/10.1155/2022/9494981
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.